Phase 1 Study of Trametinib + Ceritinib in Patients with Unresectable Melanoma
The main purpose of this study is to determine the benefit of a drug named ceritinib (ZYKADIA) in patients who have progressed on prior melanoma therapy.
PRIMARY OBJECTIVE: To determine the overall response rate (ORR) of ceritinib (per RECIST 1.1 criteria). ORR will be defined by proportion of patients who have achieved a complete response (CR) or partial response (PR) per RECIST v1.1 criteria.
Ceritinib (Zykadia); GSK1120212 (Trametinib); Trametinib ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.